Literature DB >> 18080412

Pattern recognition by B cells: the role of antigen repetitiveness versus Toll-like receptors.

H J Hinton1, A Jegerlehner, M F Bachmann.   

Abstract

Viruses induce excellent antibody responses due to several intrinsic features. Their repetitive, organised structure is optimal for the activation of the B cell receptor (BCR), leading to an increased humoral response and a decreased dependence on T cell help. Viruses also trigger Toll-like receptors (TLRs), which in addition to increasing overall Ig levels, drive the switch to the IgG2a isotype. This isotype is more efficient in viral and bacterial clearance and will activate complement, which in turn lowers the threshold of BCR activation. Exploiting these characteristics in vaccine design may help us to create vaccines which are as safe as a recombinant vaccine yet still as effective as a virus in inducing B cell responses.

Mesh:

Substances:

Year:  2008        PMID: 18080412     DOI: 10.1007/978-3-540-73900-5_1

Source DB:  PubMed          Journal:  Curr Top Microbiol Immunol        ISSN: 0070-217X            Impact factor:   4.291


  22 in total

1.  DNA vaccination in the skin using microneedles improves protection against influenza.

Authors:  Jae-Min Song; Yeu-Chun Kim; Eunju O; Richard W Compans; Mark R Prausnitz; Sang-Moo Kang
Journal:  Mol Ther       Date:  2012-04-17       Impact factor: 11.454

Review 2.  Toll-like receptors and B-cell receptors synergize to induce immunoglobulin class-switch DNA recombination: relevance to microbial antibody responses.

Authors:  Egest J Pone; Hong Zan; Jingsong Zhang; Ahmed Al-Qahtani; Zhenming Xu; Paolo Casali
Journal:  Crit Rev Immunol       Date:  2010       Impact factor: 2.214

3.  Biomaterials at the interface of nano- and micro-scale vector-cellular interactions in genetic vaccine design.

Authors:  Charles H Jones; Anders P Hakansson; Blaine A Pfeifer
Journal:  J Mater Chem B       Date:  2014-09-12       Impact factor: 6.331

Review 4.  Bacteriophage T4 nanoparticles for vaccine delivery against infectious diseases.

Authors:  Pan Tao; Jingen Zhu; Marthandan Mahalingam; Himanshu Batra; Venigalla B Rao
Journal:  Adv Drug Deliv Rev       Date:  2018-07-06       Impact factor: 15.470

5.  Engaging adaptive immunity with biomaterials.

Authors:  Carolina Mora-Solano; Joel H Collier
Journal:  J Mater Chem B       Date:  2014-05-07       Impact factor: 6.331

6.  Design of a Peptide-Carrier Vaccine Based on the Highly Immunogenic Fasciola hepatica Leucine Aminopeptidase.

Authors:  Cecilia Salazar; José F Tort; Carlos Carmona
Journal:  Methods Mol Biol       Date:  2020

7.  Guiding plant virus particles to integrin-displaying cells.

Authors:  Marisa L Hovlid; Nicole F Steinmetz; Burkhardt Laufer; Jolene L Lau; Jane Kuzelka; Qian Wang; Timo Hyypiä; Glen R Nemerow; Horst Kessler; Marianne Manchester; M G Finn
Journal:  Nanoscale       Date:  2012-05-15       Impact factor: 7.790

8.  Durable antibody responses following one dose of the bivalent human papillomavirus L1 virus-like particle vaccine in the Costa Rica Vaccine Trial.

Authors:  Mahboobeh Safaeian; Carolina Porras; Yuanji Pan; Aimee Kreimer; John T Schiller; Paula Gonzalez; Douglas R Lowy; Sholom Wacholder; Mark Schiffman; Ana C Rodriguez; Rolando Herrero; Troy Kemp; Gloriana Shelton; Wim Quint; Leen-Jan van Doorn; Allan Hildesheim; Ligia A Pinto
Journal:  Cancer Prev Res (Phila)       Date:  2013-11

Review 9.  Influence of dendritic cells on viral pathogenicity.

Authors:  Giulia Freer; Donatella Matteucci
Journal:  PLoS Pathog       Date:  2009-07-31       Impact factor: 6.823

10.  Decoration of T-independent antigen with ligands for CD22 and Siglec-G can suppress immunity and induce B cell tolerance in vivo.

Authors:  Bao Hoa Duong; Hua Tian; Takayuki Ota; Gladys Completo; Shoufa Han; José Luis Vela; Miyo Ota; Michael Kubitz; Nicolai Bovin; James C Paulson; James Paulson; David Nemazee
Journal:  J Exp Med       Date:  2009-12-28       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.